PCRX
Pacira Pharmaceuticals, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Fri, Dec. 2, 12:33 PM
    • Janney Capital initiates coverage on Pacira Pharmaceuticals (PCRX +1.3%) with a Neutral rating and $31 (0% upside) price target. Other shops rate in similarly or Buy with price targets ranging from $35 - 89.
    • The company relies on local analgesic EXPAREL (bupivacaine liposome injectable suspension) for almost all of its revenue. Label-expanding clinical trials are ongoing.
    | Fri, Dec. 2, 12:33 PM | 1 Comment
  • Wed, Nov. 2, 10:11 AM
    • Pacira Pharmaceuticals (PCRX +2.6%) Q3 results: Revenues: $68.4M (+10.0%); Operating Loss: ($20.9M); Net Loss: ($22.2M); Loss Per Share: ($0.59); Non-GAAP EPS: $0.20 (-37.5%); Quick Assets: $161.1M (+1.3%).
    • 2016 Guidance: EXPAREL net product sales: $263M - 268M; Non-GAAP R&D Expense: $40M - 50M; Non-GAAP SG&A Expense: $125M - 135M.
    | Wed, Nov. 2, 10:11 AM
  • Wed, Nov. 2, 7:34 AM
    • Pacira Pharmaceuticals (NASDAQ:PCRX): Q3 EPS of $0.20 beats by $0.22.
    • Revenue of $68.36M (+9.9% Y/Y) beats by $1.2M.
    • Press Release
    | Wed, Nov. 2, 7:34 AM
  • Tue, Nov. 1, 5:30 PM
  • Fri, Oct. 28, 1:02 PM
    • United Therapeutics (NASDAQ:UTHR) upgraded to Buy from Neutral by Ladenburg Thalmann. Price target raised to $138 (18% upside) from $128.
    • NeoGenomics (NASDAQ:NEO) upgraded to Buy from Neutral with a $10 (25% upside) price target by BTIG Research.
    • Pacira Pharmaceuticals (NASDAQ:PCRX) upgraded to Market Perform from Underperform by BMO Capital. Price target raised to $36 (8% upside) from $35.
    • Alkermes (NASDAQ:ALKS) upgraded to Overweight from Neutral by JPMorgan. Price target raised to $78 (53% upside) from $51.
    • McKesson (NYSE:MCK) downgraded to Neutral from Outperform by Baird. Price target lowered to $164 (34% upside) from $200. Also downgraded by Standpoint Research, Deutsche Bank and Leerink Swann.
    • Community Health Systems (NYSE:CYH) downgraded to Underperform from Neutral by Baird. Price target lowered to $8 (47% upside) from $12.
    • TeamHealth Holdings (NYSE:TMH) downgraded to Market Perform from Outperform by Leerink Swann. Price target raised to $43 (17% upside) from $40..
    • ARIAD Pharmaceuticals (NASDAQ:ARIA) downgraded to Market Perform from Market Outperform by JMP Securities. Price target raised to $9.37 (7% upside) from $4.37.
    • Vertex Pharmaceuticals (NASDAQ:VRTX) downgraded to Neutral from Buy by H.C. Wainwright. Price target lowered to $85 (8% upside) from $155.
    • Teva Pharmaceutical Industries (NASDAQ:TEVA) downgraded to Neutral from Buy by Mizuho. Price target lowered to $45 (7% upside) from $64.
    | Fri, Oct. 28, 1:02 PM | 5 Comments
  • Wed, Sep. 21, 12:48 PM
    | Wed, Sep. 21, 12:48 PM | 3 Comments
  • Wed, Sep. 21, 11:01 AM
    | Wed, Sep. 21, 11:01 AM | 26 Comments
  • Fri, Sep. 9, 9:51 AM
    • Quest Diagnostics (NYSE:DGX) initiated with Neutral rating and $86 (4% upside) price target by Citigroup.
    • Seattle Genetics (NASDAQ:SGEN) initiated with Overweight rating and $60 (19% upside) price target by Morgan Stanley.
    • Pacira Pharmaceuticals (NASDAQ:PCRX) initiated with Market Perform rating by Cowen & Company.
    • Medpace Holdings (Pending:MEDP) initiated with Outperform rating and $35 (19% upside) price target by Credit Suisse. Initiated with Buy rating and $35 price target by UBS.
    • Gemphire Therapeutics (Pending:GEMP) initiated with Buy rating and $20 (61% upside) price target by Laidlaw.
    • DaVita Healthcare (NYSE:DVA) initiated with Neutral rating and $71 (11% upside) price target by Citigroup.
    • AbbVie (NYSE:ABBV) initiated with Outperform rating and $82 (29% upside) price target by Raymond James.
    • Spark Therapeutics (NASDAQ:ONCE) initiated with Buy rating and $73 (23% upside) price target by Stifel Nicolaus.
    | Fri, Sep. 9, 9:51 AM
  • Thu, Aug. 4, 12:55 PM
    | Thu, Aug. 4, 12:55 PM | 1 Comment
  • Thu, Aug. 4, 11:00 AM
    | Thu, Aug. 4, 11:00 AM | 1 Comment
  • Thu, Aug. 4, 9:16 AM
    | Thu, Aug. 4, 9:16 AM | 2 Comments
  • Thu, Aug. 4, 7:31 AM
    • Pacira Pharmaceuticals (NASDAQ:PCRX): Q2 EPS of $0.19 beats by $0.16.
    • Revenue of $69.64M (+17.7% Y/Y) beats by $2.26M.
    • Press Release
    | Thu, Aug. 4, 7:31 AM
  • Wed, Aug. 3, 5:30 PM
  • Fri, Jul. 1, 10:28 AM
    • GlaxoSmithKline (NYSE:GSK) upgraded to Buy from Neutral by Citigroup. Price target is 1800p (14% upside).
    • Alexion Pharmaceuticals (NASDAQ:ALXN) upgraded to Buy from Neutral by Citigroup. Price target is $154 (29% upside).
    • IPG Photonics (NASDAQ:IPGP) upgraded to Buy from Hold by Canaccord Genuity. Price target raised to $90 (13% upside) from $85.
    • Centene (NYSE:CNC) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $86 (21% upside) from $84.
    • Pacira Pharmaceuticals (NASDAQ:PCRX) downgraded to Hold from Buy by Brean Capital.
    • TESARO (NASDAQ:TSRO) downgraded to Hold from Buy by Jefferies.
    • Esperion Therapeutics (NASDAQ:ESPR) downgraded to Equal Weight from Overweight with a $13 (26% upside) price target (from $28) by Barclays. Downgraded to Neutral from Overweight with a $15 (46% upside) price target (from $50) by JPMorgan. Downgraded to Underperform from Neutral with a $10 (0% upside) price target (from $23) by Credit Suisse.
    • HeartWare International (NASDAQ:HTWR) downgraded to Market Perform from Outperform by Wells Fargo. Downgraded to Neutral from Buy with a $58 (0% upside) price target (from $60) by SunTrust Robinson Humphrey.
    • Regulus Therapeutics (NASDAQ:RGLS) downgraded to Market Perform from Outperform by BMO Capital. Price target lowered to $4 (30% upside) from $16.
    • HealthSouth (NYSE:HLS) downgraded to Underweight from Equal Weight by Barclays. Price target lowered to $42 (8% upside) from $45.
    • SciQuest (NASDAQ:SQI) downgraded to Market Perform from Outperform by Raymond James.
    • Quest Diagnostics (NYSE:DGX) downgraded to from Neutral to Sell by Jyske Bank.
    | Fri, Jul. 1, 10:28 AM | 5 Comments
  • Fri, Jul. 1, 10:08 AM
    • Invitae (NYSE:NVTA) initiated with Hold rating with an $8.50 (18% upside) price target by Benchmark.
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) initiated with Outperform rating and $190 (33% upside) price target by BMO.
    • Pacira Pharmaceuticals (NASDAQ:PCRX) initiated with Underperform rating and $36 (4% upside) price target by BMO.
    • Mallinckrodt (NYSE:MNK) initiated with Outperform rating and $84 (35% upside) price target by BMO.
    • Horizon Pharma plc (NASDAQ:HZNP) initiated with Outperform rating and $29 (71% upside) price target by BMO.
    • Regeneron Pharmaceuticals (NASDAQ:REGN) initiated with an Outperform rating and $400 (13% upside) price target by Bernstein.
    • Biogen (NASDAQ:BIIB) initiated with an Outperform rating and $282 (15% upside) price target by Bernstein.
    • Amgen (NASDAQ:AMGN) initiated with Market Perform rating and $161 (5% upside) price target by Bernstein.
    • Lannett Company (NYSE:LCI) initiated with Hold rating and $26 (5% upside) price target by Deutsche Bank.
    • OpGen (NASDAQ:OPGN) initiated with Buy rating and $2.50 (66% upside) price target by Rodman & Renshaw.
    • Valeant Pharmaceuticals (NYSE:VRX) initiated with Market Perform rating and $26 (22% upside) price target by BMO.
    • Neurocrine Biosciences (NASDAQ:NBIX) initiated with Outperform rating and $80 (75% upside) price target by H.C. Wainwright.
    • Healthstream (NASDAQ:HSTM) initiated with Outperform rating and $30 (12% upside) price target by Barrington Research.
    • Neurometrix (NASDAQ:NURO) initiated with Buy rating and $4.50 (165% upside) price target by Rodman & Renshaw.
    • Vascular Biogenics (NASDAQ:VBLT) initiated with Buy rating and $11 (139% upside) price target by H.C. Wainwright.
    | Fri, Jul. 1, 10:08 AM | 7 Comments
  • Fri, Jul. 1, 7:58 AM
    • Pacira Pharmaceuticals (NASDAQ:PCRX) will terminate its distribution agreement with CrossLink BioScience, LLC for the promotion and sale of pain med EXPAREL (bupivacaine liposome injectable suspension) on September 30. The action will require Pacira to disgorge a $7.3M termination fee to CrossLink, payable quarterly over two years beginning in Q4.
    • Pacira will account for the fee this quarter. It will be excluded from its previously announced non-GAAP SG&A guidance of $125M - 135M due to its non-recurring nature.
    | Fri, Jul. 1, 7:58 AM | 1 Comment